Varian debuts new version of Eclipse with AI

Radiation therapy vendor Varian Medical Systems has added new artificial intelligence...Read more on AuntMinnie.comRelated Reading: Varian gets FDA nod for Ethos adaptive therapy unit Varian posts strong Q1 sales growth as profit slips Varian installs systems in Africa, U.S. Varian awarded Mich. cancer software contract Varian posts continued revenue gains in Q4, fiscal 2019
Source: Headlines - Category: Radiology Source Type: news

Related Links:

Publication date: Available online 30 May 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Renjie Wang, Zhengwei Cao, Lan Wei, Lin Bai, Hui Wang, Shiyi Zhou, Shuyue Zhan, Bin Ji, Zibo Li, Shi Gao, Jin Xie, Qingjie Ma
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Conclusions: Hypothyroidism and difficult airways are a common sequel of RT. Selected cancer patients with subclinical hypothyroidism had a smooth perioperative course.
Source: Indian Journal of Anaesthesia - Category: Anesthesiology Authors: Source Type: research
Conclusion: Conversion surgery offers benefits in terms of increase survival for initially UR-PDAC for patients who responded favorably to chemo(radiation)therapy when combined with postoperative adjuvant chemotherapy.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conditions:   Locally Advanced Rectal Carcinoma;   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v8;   Stage IIA Rectal Cancer AJCC v8;   Stage IIB Rectal Cancer AJCC v8;   Stage IIC Rectal Cancer AJCC v8;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Rectal Can cer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8 Inte...
Source: - Category: Research Source Type: clinical trials
Conclusions: Menopausal symptoms were prevalent in this population. Our data indicate that women are experiencing climacteric symptoms, but are overall unmotivated to address symptoms using HT. Factors such as symptom severity, fear of side effects, income level, or education level were not associated with acceptability of HT for premature menopause.
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
ConclusionsLow ‐dose hilar SBRT was efficacious and well‐tolerated, with impressive overall survival and no grade ≥ 3 toxicity. Repeat treatments with SBRT were feasible and effective, demonstrating overall survival, local control, and toxicity comparable to primary treatments.Key pointsSignificant findings of the study Low ‐dose hilar SBRT was efficacious and well‐tolerated Repeated treatments with SBRT demonstrated encouraging results, comparable to primary treatmentsWhat this study adds This study contributes to the small body of literature concerning hilar SBRT Repeat hilar SBRT was safe and fe...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsIn our study, besides the known dosimetric factors, DM was found to be the most important risk factor causing RP development in multivariate analysis and RPA.The risk is tripled compared to patients without DM.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Perioperative chemotherapy has become a standard treatment for muscle invasive bladder cancer and is recommended by national and international guidelines. The treatment of metastatic urothelial cancer evolved by the use of immune-modulating therapies like checkpoint inhibitors. Many clinical trials have been initiated which try to evaluate the role of immune checkpoint inhibition in the neoadjuvant and adjuvant setting. These trials focus not only on monotherapy, but also on the combination of checkpoint inhibitors with classical chemotherapy or with local radiation therapy (radioimmunotherapy). In n...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
Publication date: Available online 21 May 2020Source: Practical Radiation OncologyAuthor(s): Mark G. Trombetta, Anthony Dragun, Nina A. Mayr, Lori J. Pierce
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Siemens Healthineers subsidiary PETNet Solutions and Zionexa have announced...Read more on AuntMinnie.comRelated Reading: ASTRO: Radiation therapy slashes breast cancer recurrence MRI + mammography detects recurrent breast cancer Blue Earth, PETNet expand Axumin distribution SNMMI: FDG-PET predicts breast cancer outcomes Blue Earth, PETNet roll out Axumin
Source: Headlines - Category: Radiology Source Type: news
More News: African Health | Cancer | Cancer & Oncology | Contracts | Radiation Therapy | Radiology